134 related articles for article (PubMed ID: 38018812)
41. Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.
Koshikawa H; Tsukie T; Kurita A; Fujikura M; Suzuki M; Araki K
J Infect Chemother; 2017 Nov; 23(11):798-799. PubMed ID: 28506529
[TBL] [Abstract][Full Text] [Related]
42. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Hashimoto M; Nakayama T; Fujimoto S; Inoguchi S; Nishimoto M; Kikuchi T; Adomi S; Banno E; De Velasco MA; Saito Y; Shimizu N; Mori Y; Minami T; Fujita K; Nozawa M; Nose K; Yoshimura K; Uemura H
Anticancer Drugs; 2022 Jan; 33(1):e818-e821. PubMed ID: 34486537
[TBL] [Abstract][Full Text] [Related]
43. Pazopanib-induced enteritis in a patient with renal cell carcinoma.
Ariyoshi M; Hayashi R; Takasago T; Yamashita K; Hiyama Y; Yuge R; Urabe Y; Ueno Y; Shimamoto F; Oka S
Clin J Gastroenterol; 2024 Jun; 17(3):434-440. PubMed ID: 38407743
[TBL] [Abstract][Full Text] [Related]
44. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
45. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
46. Rapid and fatal acute heart failure induced by pazopanib.
van Marcke C; Ledoux B; Petit B; Seront E
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26336188
[TBL] [Abstract][Full Text] [Related]
47. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
[TBL] [Abstract][Full Text] [Related]
48. Importance of Therapeutic Drug Monitoring to Detect Drug Interaction between Pazopanib and Warfarin: A Case Report.
Takasaki S; Adachi H; Kawasaki Y; Kikuchi M; Ito A; Mano N
J Pharm Pharm Sci; 2020; 23():200-205. PubMed ID: 32407286
[TBL] [Abstract][Full Text] [Related]
49. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
50. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
[TBL] [Abstract][Full Text] [Related]
51. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
52. Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma - A Single Institute Analysis.
Wang X; Nakano K; Shiga T; Ohmoto A; Oyakawa T; Ebihara A; Sato Y; Fukuda N; Nishizawa M; Urasaki T; Ono M; Yunokawa M; Tomomatsu J; Takahashi S
Circ J; 2024 Jan; 88(2):228-233. PubMed ID: 35314578
[TBL] [Abstract][Full Text] [Related]
53. The Impact of Pazopanib on the Cardiovascular System.
Justice CN; Derbala MH; Baich TM; Kempton AN; Guo AS; Ho TH; Smith SA
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):387-398. PubMed ID: 29706106
[TBL] [Abstract][Full Text] [Related]
54. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
55. Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases.
Güzel HG; Kıvrak Salim D
J Oncol Pharm Pract; 2024 Jan; 30(1):215-219. PubMed ID: 37724017
[TBL] [Abstract][Full Text] [Related]
56. Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.
Kempton A; Justice C; Guo A; Cefalu M; Makara M; Janssen P; Ho TH; Smith SA
Clin Exp Hypertens; 2018; 40(6):524-533. PubMed ID: 29172746
[TBL] [Abstract][Full Text] [Related]
57. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
Abdallah AO; Vallurupalli S; Kunthur A
J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
[No Abstract] [Full Text] [Related]
58. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
[TBL] [Abstract][Full Text] [Related]
59. Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
Amaro F; Pisoeiro C; Valente MJ; Bastos ML; Guedes de Pinho P; Carvalho M; Pinto J
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077297
[TBL] [Abstract][Full Text] [Related]
60. Heart Failure: A Paraneoplastic Manifestation of Renal Cell Carcinoma - Reversed With Pazopanib.
Pandey M; Gandhi S; George S
Clin Genitourin Cancer; 2017 Oct; 15(5):e835-e837. PubMed ID: 28410910
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]